In conclusion, we report the design, synthesis, characterization and functional validation of ET‐CORM–Ab, a CatB–activated, antibody‐conjugated carbon monoxide‐releasing molecule that enables targeted CO delivery to HER2‐overexpressing cancer cells. This evidence concerns the gene TYRP1 and cancer.